JPH11510151A - 日本脳炎ワクチンの工業的製造方法と、それによって得られるワクチン - Google Patents
日本脳炎ワクチンの工業的製造方法と、それによって得られるワクチンInfo
- Publication number
- JPH11510151A JPH11510151A JP50729097A JP50729097A JPH11510151A JP H11510151 A JPH11510151 A JP H11510151A JP 50729097 A JP50729097 A JP 50729097A JP 50729097 A JP50729097 A JP 50729097A JP H11510151 A JPH11510151 A JP H11510151A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- japanese encephalitis
- growth medium
- suspension
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 title claims abstract description 5
- 241000700605 Viruses Species 0.000 claims abstract description 80
- 238000003306 harvesting Methods 0.000 claims abstract description 29
- 241000710842 Japanese encephalitis virus Species 0.000 claims abstract description 23
- 239000001963 growth medium Substances 0.000 claims abstract description 21
- 239000000725 suspension Substances 0.000 claims abstract description 17
- 238000004113 cell culture Methods 0.000 claims abstract description 8
- 206010014596 Encephalitis Japanese B Diseases 0.000 claims abstract description 7
- 201000005807 Japanese encephalitis Diseases 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 6
- 238000003860 storage Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- 230000002779 inactivation Effects 0.000 claims description 13
- 210000003501 vero cell Anatomy 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 238000004255 ion exchange chromatography Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 5
- 238000005377 adsorption chromatography Methods 0.000 claims description 4
- 238000010899 nucleation Methods 0.000 claims description 3
- 239000012737 fresh medium Substances 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 abstract description 2
- 108091092356 cellular DNA Proteins 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 238000001459 lithography Methods 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 19
- 239000002609 medium Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000356 contaminant Substances 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- -1 polysaccharide sulfate Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 239000012541 Fractogel® Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 241000609532 mosquito-borne viruses Species 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 下記段階(a)〜(f)からなる日本脳炎に対するワクチンの工業的製造方法: (a) 細胞株に由来する細胞を培養し、 (b) 得られた細胞培養物にウィルス増殖培地の存在下で日本脳炎ウィルスを接種 し、 (c) 細胞でウィルスを増殖させ、 (d) 細胞によって産生されたウィルスの懸濁液を構成するウィルス増殖培地を収 穫し、 (e) 少なくとも1つのイオン交換クロマトグラフィー段階とゲルパーミエーショ ン段階とによってウィルス懸濁液を精製し、 (f) 使用時まで確実に保存するためにウィルス懸濁液を医薬品の状態に処方する 。 2. 播種に用いるウィルス量が感染効率0.1以下に相当する請求項1に記載の 方法。 3. 精製段階(e)の前または後にウィルス懸濁液の不活性化段階を行う請求項 1または2に記載の方法。 4. 不活性化を化学薬品を用いて室温で行う請求項1〜3のいずれか一項に記 載の方法。 5. ウィルス増殖に用いる細胞がベロ細胞である請求項1〜4のいずれか一項 に記載の方法。 6. 下記操作で精製を行う請求項1〜5のいずれか一項に記載の方法: (a) イオン交換クロマトグラフィー (b) 吸着クロマトグラフィー (c) ゲルパーミエーション。 7. 収穫段階(d)の後に、新しいウィルス増殖培地を再び導入し、ウィルスが 増殖するのに十分な時間をおいてから再びウィルス増殖培地の収穫を行う請求項 1〜6のいずれか一項に記載の方法。 8. ウィルス増殖培地を収穫して新しい培地で置き換える操作を1〜7回行う 請求項7に記載の方法。 9. 段階(d)の後に収穫したウィルス懸濁液を濾過する請求項1〜8のいずれ か一項に記載の方法。 10. ウイルス増殖培地の蛋白質濃度が5g/l以下である請求項1〜9のいずれか 一項に記載の方法。 11. 細胞株に由来する細胞で培養して得られる日本脳炎ウィルスからなる、細 胞DNA含有率が100pg/doseであることを特徴とする日本脳炎ワクチン。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9509374A FR2737412B1 (fr) | 1995-08-01 | 1995-08-01 | Procede de production d'un vaccin contre le virus de l'encephalite japonaise et vaccin obtenu par ce procede |
FR95/09374 | 1995-08-01 | ||
FR96/03638 | 1996-03-22 | ||
FR9603638A FR2746411B3 (fr) | 1996-03-22 | 1996-03-22 | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
PCT/FR1996/001195 WO1997004803A1 (fr) | 1995-08-01 | 1996-07-29 | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11510151A true JPH11510151A (ja) | 1999-09-07 |
Family
ID=26232139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50729097A Pending JPH11510151A (ja) | 1995-08-01 | 1996-07-29 | 日本脳炎ワクチンの工業的製造方法と、それによって得られるワクチン |
Country Status (11)
Country | Link |
---|---|
US (1) | US6149917A (ja) |
EP (1) | EP0841942B2 (ja) |
JP (1) | JPH11510151A (ja) |
KR (1) | KR19990036028A (ja) |
CN (1) | CN1122531C (ja) |
AT (1) | ATE231729T1 (ja) |
AU (1) | AU709584B2 (ja) |
CA (1) | CA2228128C (ja) |
DE (1) | DE69626022T3 (ja) |
NZ (1) | NZ315357A (ja) |
WO (1) | WO1997004803A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4751558B2 (ja) * | 2000-04-07 | 2011-08-17 | 一般財団法人化学及血清療法研究所 | 日本脳炎不活化ワクチン及びその製造方法 |
US9283542B2 (en) | 2009-06-25 | 2016-03-15 | Jnc Corporation | Chromatography medium, preparation method of the same, and method for producing virus vaccine using the chromatography medium |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100503701B1 (ko) * | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법 |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6207439B1 (en) | 1997-03-25 | 2001-03-27 | Center For Disease Control | Purification of Japanese encephalitis virus |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
JP2000083657A (ja) * | 1998-07-13 | 2000-03-28 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスワクチン |
AU743546B2 (en) | 1998-10-05 | 2002-01-31 | Research Foundation For Microbial Diseases Of Osaka University, The | Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same |
US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
ES2328466T3 (es) * | 2001-03-27 | 2009-11-13 | Vertex Pharmaceuticals Incorporated | Composiciones y metodos utiles para la infeccion por hcv. |
CN1305526C (zh) * | 2003-12-29 | 2007-03-21 | 薛平 | 乙型脑炎病毒裂解疫苗及其制备方法 |
CA2586107A1 (en) | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | A novel method for the production and purification of adenoviral vectors |
EP1724338A1 (en) * | 2005-05-19 | 2006-11-22 | Crucell Holland B.V. | Methods for the production of a whole-inactivated West Nile Virus vaccine |
WO2006122964A1 (en) * | 2005-05-19 | 2006-11-23 | Crucell Holland B.V. | Methods for the production of a whole-inactivated west nile virus vaccine |
KR101623994B1 (ko) | 2007-12-26 | 2016-05-24 | 기타사토 다이이치 산쿄 백신 가부시키가이샤 | 안정하게 장기간 보존할 수 있는 일본뇌염 백신의 제조방법 및 그 백신의 용도 |
WO2010137036A2 (en) * | 2009-05-25 | 2010-12-02 | Panacea Biotec Ltd | Novel japanese encephalitis vaccine and method of manufacturing the same |
AR078253A1 (es) * | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
CN102327608B (zh) * | 2010-08-27 | 2013-03-27 | 丽珠集团疫苗工程股份有限公司 | 一种乙型脑炎疫苗的纯化方法 |
DK2675476T3 (en) * | 2011-02-17 | 2015-12-14 | Boehringer Ingelheim Vetmed | Process for producing PRRSV on a commercial scale |
EP2968513A2 (en) | 2013-03-15 | 2016-01-20 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use |
CA3010049C (en) * | 2016-01-15 | 2021-10-12 | The Chemo-Sero-Therapeutic Research Institute | Vaccine containing immobilized virus particles |
EP3420076B1 (en) | 2017-03-06 | 2024-02-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
EP4382183A2 (en) | 2017-03-06 | 2024-06-12 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6147185A (ja) * | 1984-08-09 | 1986-03-07 | Chemo Sero Therapeut Res Inst | 日本脳炎ウイルスの精製方法 |
US4637936A (en) * | 1984-08-10 | 1987-01-20 | Marlen Research Corporation | Aspetic food processing apparatus and method |
AT393356B (de) * | 1989-12-22 | 1991-10-10 | Immuno Ag | Verfahren zur herstellung von fsme-virus-antigen |
CA2047041A1 (en) † | 1990-07-18 | 1992-01-19 | John A. Lewis | Process for purification of hepatitis-a virus capsids |
GB9022547D0 (en) † | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
JPH06153227A (ja) † | 1992-10-29 | 1994-05-31 | Victor Co Of Japan Ltd | カラー信号補正回路 |
CN1063970C (zh) * | 1994-12-06 | 2001-04-04 | 卫生部北京生物制品研究所 | 用鳞翅目粘虫卵巢细胞制备流行性乙脑疫苗的方法及疫苗 |
-
1996
- 1996-07-29 EP EP96927102A patent/EP0841942B2/fr not_active Expired - Lifetime
- 1996-07-29 CA CA 2228128 patent/CA2228128C/fr not_active Expired - Fee Related
- 1996-07-29 DE DE1996626022 patent/DE69626022T3/de not_active Expired - Lifetime
- 1996-07-29 WO PCT/FR1996/001195 patent/WO1997004803A1/fr active IP Right Grant
- 1996-07-29 KR KR1019980700693A patent/KR19990036028A/ko not_active Application Discontinuation
- 1996-07-29 AT AT96927102T patent/ATE231729T1/de not_active IP Right Cessation
- 1996-07-29 NZ NZ31535796A patent/NZ315357A/xx not_active IP Right Cessation
- 1996-07-29 AU AU67041/96A patent/AU709584B2/en not_active Expired
- 1996-07-29 US US09/000,263 patent/US6149917A/en not_active Expired - Lifetime
- 1996-07-29 JP JP50729097A patent/JPH11510151A/ja active Pending
- 1996-07-29 CN CN96196620A patent/CN1122531C/zh not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4751558B2 (ja) * | 2000-04-07 | 2011-08-17 | 一般財団法人化学及血清療法研究所 | 日本脳炎不活化ワクチン及びその製造方法 |
US9283542B2 (en) | 2009-06-25 | 2016-03-15 | Jnc Corporation | Chromatography medium, preparation method of the same, and method for producing virus vaccine using the chromatography medium |
Also Published As
Publication number | Publication date |
---|---|
EP0841942B2 (fr) | 2007-12-12 |
AU6704196A (en) | 1997-02-26 |
DE69626022D1 (de) | 2003-03-06 |
NZ315357A (en) | 1999-08-30 |
DE69626022T2 (de) | 2003-09-11 |
KR19990036028A (ko) | 1999-05-25 |
WO1997004803A1 (fr) | 1997-02-13 |
EP0841942B1 (fr) | 2003-01-29 |
AU709584B2 (en) | 1999-09-02 |
CN1122531C (zh) | 2003-10-01 |
EP0841942A1 (fr) | 1998-05-20 |
ATE231729T1 (de) | 2003-02-15 |
CN1194584A (zh) | 1998-09-30 |
CA2228128C (fr) | 2011-03-29 |
CA2228128A1 (fr) | 1997-02-13 |
US6149917A (en) | 2000-11-21 |
DE69626022T3 (de) | 2008-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11510151A (ja) | 日本脳炎ワクチンの工業的製造方法と、それによって得られるワクチン | |
JP3313117B2 (ja) | ウイルス粒子の効率の高い生産および単離 | |
RU2144081C1 (ru) | Способ крупномасштабного производства устойчивой при хранении композиции тромбина терапевтической степени чистоты | |
WO2015059714A1 (en) | Emergency mode in a hybrid vehicle | |
US4199450A (en) | Process of separating from an aqueous medium a protein or a morphologically organized unit by liquid exclusion chromatography | |
CA2056437C (en) | Production of virus and purification of viral envelope proteins for vaccine use | |
EP2075005B1 (en) | Ipv-dpt vaccine | |
US4814277A (en) | Method of inactivating reproductive filterable pathogens | |
CN105396129A (zh) | 一种利用脊髓灰质炎减毒株生产的灭活疫苗 | |
CN105396128A (zh) | 一种纯化脊髓灰质炎病毒液的方法 | |
JP2000083657A (ja) | 日本脳炎ウイルスワクチン | |
JPH01230533A (ja) | 抗エイズウイルス抗体陽性静注用免疫グロブリン製剤の製造方法 | |
JP3747077B2 (ja) | 百日咳菌由来感染防御成分の分離取得方法 | |
CN116554281A (zh) | 一种口蹄疫病毒衣壳蛋白病毒样颗粒的纯化方法 | |
JP4706093B2 (ja) | パルボウイルスの除去方法及び精製方法 | |
DE3726879A1 (de) | Verfahren zur herstellung von rekombinanten vakzinen gegen hepatitis b | |
FR2737412A1 (fr) | Procede de production d'un vaccin contre le virus de l'encephalite japonaise et vaccin obtenu par ce procede | |
FR2746411A1 (fr) | Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041130 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050411 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060131 |